476471-33-7

Basic information

• Product Name: 2-Pyridinecarboxamide, N-methoxy-N,6-dimethyl-
• Synonyms: 6-methylpyridine-2-carboxylic acid methoxy-methyl-amide;6-methylpyridine-2-carboxylic acid N-methoxy-N-methylamide;6-methyl-pyridine-2-carboxylic acid N-methoxy-N-methyl-amide
• CAS NO: 476471-33-7
• Molecular Formula: C9H12N2O2
• Molecular Weight: 180.206
• Mol File: 476471-33-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 2-Pyridinecarboxamide, N-methoxy-N,6-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Pyridinecarboxamide, N-methoxy-N,6-dimethyl-(476471-33-7)
• EPA Substance Registry System: 2-Pyridinecarboxamide, N-methoxy-N,6-dimethyl-(476471-33-7)

Safety Data

• Hazardous Substances Data: 476471-33-7(Hazardous Substances Data)

Upstream product

• 934-60-1 6-methyl-2-pyridinecarboxylic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 

Downstream Products

• 6940-57-4 2-acetyl-6-methylpyridine 

Relevant articles and documents

SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS

The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline

The ATP-synthase inhibitor bedaquiline is effective against drug-resistant tuberculosis but is extremely lipophilic (clogP 7.25) with a very long plasma half-life. Additionally, inhibition of potassium current through the cardiac hERG channel by bedaquiline, is associated with prolongation of the QT interval, necessitating cardiovascular monitoring. Analogues were prepared where the naphthalene C-unit was replaced with substituted pyridines to produce compounds with reduced lipophilicity, anticipating a reduction in half-life. While there was a direct correlation between in vitro inhibitory activity against M. tuberculosis (MIC90) and compound lipophilicity, potency only fell off sharply below a clogP of about 4.0, providing a useful lower bound for analogue design. The bulk of the compounds remained potent inhibitors of the hERG potassium channel, with notable exceptions where IC50 values were at least 5-fold higher than that of bedaquiline. Many of the compounds had desirably higher rates of clearance than bedaquiline, but this was associated with lower plasma exposures in mice, and similar or higher MICs resulted in lower AUC/MIC ratios than bedaquiline for most compounds. The two compounds with lower potency against hERG exhibited similar clearance to bedaquiline and excellent efficacy in vivo, suggesting further exploration of C-ring pyridyls is worthwhile.

Alkyl sulfonamide derivatives

This invention is directed to alkyl sulfonamide derivatives which are ligands at the NPY Y5 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.